Cargando…
Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications
Lopinavir-ritonavir combination is being used for the treatment of SARS-CoV-2 infection. A low dose of ritonavir is added to other protease inhibitors to take advantage of potent inhibition of cytochrome (CYP) P450 3A4, thereby significantly increasing the plasma concentration of coadministered lopi...
Autores principales: | Agarwal, Shubham, Agarwal, Sanjeev Kumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486594/ https://www.ncbi.nlm.nih.gov/pubmed/32918656 http://dx.doi.org/10.1007/s10557-020-07070-1 |
Ejemplares similares
-
Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir
por: Gonzalez-García, Ruben, et al.
Publicado: (2023) -
Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2–infected patient
por: Stalder, Gregoire, et al.
Publicado: (2020) -
Lichen planus after SARS-CoV-2 infection treated with lopinavir/ritonavir()
por: Gimeno Castillo, Javier, et al.
Publicado: (2021) -
Endocrine changes in SARS-CoV-2 patients and lessons from SARS-CoV
por: Agarwal, Shubham, et al.
Publicado: (2020) -
Potential drug–drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir()
por: Brandariz-Nuñez, David, et al.
Publicado: (2020)